Eric C. Jeschke
128 IP cases indexed. Covers patent matters.
Cases Presided Over
128 cases indexed | Page 3 of 5
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB held that all nine claims of Inari Medical’s hemostasis‑valve patent are unpatentable, finding anticipation by Schaffer and obviousness over combinations with Hartley, Eller and Garrison. The decision hinges on the Board’s construction that the claimed filament must be flexible, which the prior art does not disclose.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB granted Imperative Care’s petition to institute inter partes review of Inari Medical’s hemostasis‑valve patent, finding a reasonable likelihood of unpatentability for claims 1‑9.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB denied Imperative Care's petition to institute an IPR against Inari Medical's embolism‑treatment patent, finding no reasonable likelihood of unpatentability. The petition relied on anticipation and obviousness over Garrison and other references, but lacked sufficient particularity.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB held that Imperative Care proved all nine claims of Inari Medical’s 11,697,011 B2 hemostasis valve patent are unpatentable, finding the term “filament” must be flexible and that the prior art renders the claims obvious.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB decided to institute trial on all challenged claims of the '921 patent, despite preliminary evidence not supporting anticipation over Schaffer. The Board adopted a broad definition of 'filament' but ultimately found that the claim language required flexibility based on intrinsic and extrinsic teachings.
Eunsung Global Corp. v.HydraFacial LLC et al.
Eunsung Global Corp. and HydraFacial LLC settled their inter partes review disputes, leading the PTAB to terminate both IPRs before institution. The settlement agreement is treated as confidential business information.
Eunsung Global Corp. v.HydraFacial LLC et al.
Eunsung Global and HydraFacial settled their inter partes review disputes before the PTAB instituted a trial. The Board granted joint motions to terminate and to keep the settlement agreement confidential, ending the proceedings.
Imperative Care, Inc. v.Inari Medical, Inc.
The PTAB has instituted an inter partes review of Inari Medical’s 11,865,291 B2 hemostasis valve patent after finding Imperative Care’s petition shows a reasonable likelihood of success. All challenged claims (1‑8, 12‑19) are now subject to trial.
Imperative Care, Inc. v.Inari Medical, Inc.
The PTAB instituted an inter partes review of Inari Medical’s 11,697,012 B2 hemostasis valve patent after finding Imperative Care’s petition shows a reasonable likelihood of success on all nine challenged claims.
Imperative Care, Inc. v.Inari Medical, Inc.
The PTAB held that all nine claims of Inari Medical’s hemostasis‑valve patent are unpatentable. Petitioner Imperative Care proved anticipation and obviousness over Schaffer, Hartley, Eller and Garrison, with the Board emphasizing that the claimed filament must be flexible.
Imperative Care, Inc. v.Inari Medical, Inc.
The PTAB instituted an inter partes review of Inari Medical’s 11,844,921 B2 hemostasis valve patent after Imperative Care showed a reasonable likelihood of success. All challenged claims (1‑7, 9‑10, 15‑18, 20‑24) are now under review.
Imperative Care, Inc. v.Inari Medical, Inc.
The PTAB instituted an inter partes review of Inari Medical’s 11,697,011 B2 hemostasis valve patent after finding Imperative Care’s likelihood of success on at least one claim.
Imperative Care, Inc. v.Inari Medical, Inc.
The PTAB denied Imperative Care’s petition to institute an IPR against Inari Medical’s U.S. Patent 11,744,691, finding no reasonable likelihood of success. The Board concluded the cited prior art did not disclose the required negative‑pressure pump configuration.
Imperative Care, Inc. v.Inari Medical, Inc.
Imperative Care challenges Inari Medical's hemostasis valve patent (11554005) on obviousness grounds. The PTAB instituted the IPR, requiring further review of claims 1-15 based on prior art combinations.
Imperative Care, Inc. v.Inari Medical, Inc.
The PTAB denied the institution of an IPR challenge against Inari Medical's patent (11744691) covering emboli treatment systems. The Board found that the petitioner, Imperative Care, Inc., failed to demonstrate a reasonable likelihood of prevailing on its grounds of anticipation and obviousness.
Sinclair Pharma Limited et al. v.HydraFacial LLC
Sinclair Pharma Limited et al. successfully instituted IPR proceedings against HydraFacial LLC regarding skin treatment systems, finding a reasonable likelihood of obviousness over prior art references. The Board found that combining existing microdermabrasion and irrigation technologies renders the challenged claims unpatentable.
Globus Medical, Inc. v.Spinelogik, Inc.
Globus Medical successfully navigated the PTAB institution phase against Spinelogik regarding spinal fusion implants. The Board found a reasonable likelihood of prevailing based on obviousness over Moskowitz and Steffee for several key claims.
Globus Medical, Inc. v.Spinelogik, Inc.
Globus Medical successfully petitioned the PTAB to challenge Spinelogik's spinal fusion implant patents. The Board found a reasonable likelihood of unpatentability based on anticipation and obviousness over prior art references like Blain. This decision advances the dispute into active trial proceedings.
Kubota North America Corporation et al. v.Vermeer Manufacturing Company
Kubota North America Corporation successfully petitioned against Vermeer Manufacturing Company's patent, leading the PTAB to institute trial on all 28 claims. The Board found a reasonable likelihood of prevailing based on anticipation and obviousness grounds using prior art references KR996, Bares, and Beltrami.
Kubota North America Corporation et al. v.Vermeer Manufacturing Company
Kubota North America Corporation successfully petitioned the PTAB, leading to the institution of its IPR against Vermeer Manufacturing Company's patent (9321386). The Board found a reasonable likelihood that at least one claim would be unpatentable based on prior art combinations.
Kubota North America Corporation et al. v.Vermeer Manufacturing Company
Kubota North America Corporation successfully convinced the PTAB not to issue a discretionary denial of its IPR petition against Vermeer Manufacturing Company's patent. The Board found that Kubota demonstrated a reasonable likelihood of prevailing on at least one ground, allowing the case to proceed to full examination.
Kubota North America Corporation et al. v.Vermeer Manufacturing Company
Kubota North America Corporation successfully navigated the institution decision process against Vermeer Manufacturing Company's patent, leading to a trial on key claims. The Board found that the prior art was sufficiently distinct from previous PTO examinations and granted review under § 325(d).
Kubota North America Corporation et al. v.Vermeer Manufacturing Company
Kubota North America Corporation successfully petitioned for institution in an IPR against Vermeer Manufacturing Company's '386 patent, asserting grounds of obviousness (103) and novelty (102). The Board found that the petitioner's arguments regarding prior art combinations were persuasive enough to overcome the Patent Owner's request for discretionary denial.
Par-Kan Company, LLC et al. v.Unverferth Mfg. Co., Inc.
The PTAB denied the institution of an IPR challenging claims in a seed carrier patent (9745123). The Patent Owner successfully demonstrated that their prototype predated the prior art references cited by the Petitioner.
Par-Kan Company, LLC et al. v.Unverferth Mfg. Co., Inc.
The PTAB denied Par-Kan Company's IPR against Unverferth Mfg. Co.'s patent 8967940, finding that the petitioner failed to demonstrate a reasonable likelihood of prevailing over prior art references like Morris and Hiniker Webpage.
Dyson Technology Limited et al. v.Omachron Intellectual Property Inc. et al.
Dyson and Omachron settled their PTAB inter partes review disputes, leading to termination of four IPRs covering Dyson vacuum technology patents. The settlement agreement is treated as confidential business information.
Dyson Technology Limited et al. v.Omachron Intellectual Property Inc. et al.
Dyson successfully petitioned to institute IPR against Omachron Intellectual Property Inc.'s vacuum cleaner patent, asserting obviousness under 35 U.S.C. § 103. The Board found that Dyson adequately demonstrated a motivation to combine prior art references for several claimed features, leading to institution on 13 claims.
BabyBjorn AB et al. v.The Ergo Baby Carrier, Inc. et al.
The PTAB denied the institution of an IPR challenge against The Ergo Baby Carrier's patent on adjustable baby carriers. Petitioner failed to meet its burden of persuasion, specifically regarding the public accessibility of key prior art and demonstrating a reasonable likelihood of prevailing on the merits.
BabyBjorn AB et al. v.The Ergo Baby Carrier, Inc. et al.
The PTAB denied BabyBjörn AB's request to institute a second Inter Partes Review against The Ergo Baby Carrier, Inc., citing insufficient grounds for parallel proceedings.
Eunsung Global Corp. v.HydraFacial LLC et al.
The PTAB denied institution for an IPR challenge regarding skin treatment systems due to substantial overlap with parallel ITC proceedings and advanced litigation. This decision emphasizes resource conservation when multiple venues address the same prior art.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.